Prolifagen
Prolifagen is dedicated to regenerating damaged heart muscle following a heart attack using innovative microRNA (miR) technology combined with hydrogel delivery systems. Their mission is to advance the science of miR to provide effective solutions for heart tissue regeneration, addressing a significant unmet medical need and reducing the economic burden of heart disease.
Industries
Nr. of Employees
small (1-50)
Prolifagen
Philadelphia, Pennsylvania, United States, North America
Products
miR-302 hydrogel therapeutic candidate (single-application intramyocardial formulation)
A formulation combining miR-302 with a hyaluronic-acid-based hydrogel designed for localized intramyocardial administration to release microRNA over several days and induce cardiomyocyte proliferation for heart muscle regeneration.
PRO-302
A proprietary mixture of miR302 combined with a hydrogel, designed to be introduced into damaged heart muscle following a heart attack to promote cardiomyocyte proliferation and heart muscle regeneration.
PRO302
Proprietary mix delivering miRNA302 transiently to damaged heart muscle using a hydrogel-based system for cardiac regeneration.
Prolifagen microRNA Therapy
A microRNA-based therapeutic approach designed to prevent the progression from heart attack to heart failure by reactivating cardiomyocyte proliferation and reducing scar formation.
gel-miR302
An injectable hyaluronic acid hydrogel delivering miR302 mimics to the heart to promote cardiomyocyte proliferation and cardiac regeneration after myocardial infarction.
injectable hyaluronic acid hydrogel for local and sustained delivery of miR-302 mimics
An injectable hydrogel system based on modified hyaluronic acid designed for local and sustained delivery of miR-302 mimics to promote cardiomyocyte proliferation and cardiac regeneration after myocardial infarction.
miR-302 hydrogel therapeutic candidate (single-application intramyocardial formulation)
A formulation combining miR-302 with a hyaluronic-acid-based hydrogel designed for localized intramyocardial administration to release microRNA over several days and induce cardiomyocyte proliferation for heart muscle regeneration.
PRO-302
A proprietary mixture of miR302 combined with a hydrogel, designed to be introduced into damaged heart muscle following a heart attack to promote cardiomyocyte proliferation and heart muscle regeneration.
PRO302
Proprietary mix delivering miRNA302 transiently to damaged heart muscle using a hydrogel-based system for cardiac regeneration.
Prolifagen microRNA Therapy
A microRNA-based therapeutic approach designed to prevent the progression from heart attack to heart failure by reactivating cardiomyocyte proliferation and reducing scar formation.
gel-miR302
An injectable hyaluronic acid hydrogel delivering miR302 mimics to the heart to promote cardiomyocyte proliferation and cardiac regeneration after myocardial infarction.
injectable hyaluronic acid hydrogel for local and sustained delivery of miR-302 mimics
An injectable hydrogel system based on modified hyaluronic acid designed for local and sustained delivery of miR-302 mimics to promote cardiomyocyte proliferation and cardiac regeneration after myocardial infarction.
Services
Collaborative preclinical research and development activities to design, formulate, and test microRNA-hydrogel therapeutic candidates in animal models of myocardial infarction.
Collaborative preclinical research and development activities to design, formulate, and test microRNA-hydrogel therapeutic candidates in animal models of myocardial infarction.
Expertise Areas
- Cardiac regenerative medicine
- microRNA therapeutic discovery and development
- Biomaterials-based drug delivery (hydrogels)
- Preclinical efficacy studies in small and large animal models
Key Technologies
- microRNA therapeutics (miR-302)
- Hyaluronic acid hydrogel controlled-release
- Intramyocardial delivery
- Rodent and porcine preclinical models